[1]

Bang OY, Chung JW, Lee MJ, Seo WK, Kim GM, et al. 2020. Cancer-related stroke: an emerging subtype of ischemic stroke with unique pathomechanisms. Journal of stroke 22:1−10

doi: 10.5853/jos.2019.02278
[2]

Kwon HM, Kang BS, Yoon BW. 2007. Stroke as the first manifestation of concealed cancer. Journal of the Neurological Sciences 258:80−83

doi: 10.1016/j.jns.2007.02.035
[3]

Salazar-Camelo RA, Moreno-Vargas EA, Cardona AF, Bayona-Ortiz HF. 2021. Ischemic stroke: a paradoxical manifestation of cancer. Critical Reviews in Oncology/Hematology 157:103181

doi: 10.1016/j.critrevonc.2020.103181
[4]

Taccone FS, Jeangette SM, Blecic SA. 2008. First-ever stroke as initial presentation of systemic cancer. Journal of Stroke and Cerebrovascular Diseases 17:169−174

doi: 10.1016/j.jstrokecerebrovasdis.2008.01.007
[5]

Grazioli S, Paciaroni M, Agnelli G, Acciarresi M, Alberti A, et al. 2018. Cancer-associated ischemic stroke: a retrospective multicentre cohort study. Thrombosis Research 165:33−37

doi: 10.1016/j.thromres.2018.03.011
[6]

Demandante CG, Troyer DA, Miles TP. 2003. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. American Journal of Clinical Oncology 26:79−83

doi: 10.1097/00000421-200302000-00015
[7]

Liu Z, Liu C, Guo W, Li S, Bai O. 2015. Clinical analysis of 152 cases of multiple primary malignant tumors in 15, 398 patients with malignant tumors. PLoS One 10:e0125754

doi: 10.1371/journal.pone.0125754
[8]

Zhai C, Cai Y, Lou F, Liu Z, Xie J, et al. 2018. Multiple primary malignant tumors − a clinical analysis of 15,321 patients with malignancies at a single center in China. Journal of Cancer 9:2795−2801

doi: 10.7150/jca.25482
[9]

Selvik HA, Bjerkreim AT, Thomassen L, Waje-Andreassen U, Naess H, et al. 2018. When to screen ischaemic stroke patients for cancer. Cerebrovascular Diseases 45:42−47

doi: 10.1159/000484668
[10]

Dearborn JL, Urrutia VC, Zeiler SR. 2014. Stroke and cancer - a complicated relationship. Journal of Neurology & Translational Neuroscience 2:1039
[11]

Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, et al. 2014. Cryptogenic subtype predicts reduced survival among cancer patients with ischemic stroke. Stroke 45:2292−2297

doi: 10.1161/STROKEAHA.114.005784
[12]

Quintas S, Rogado J, Gullón P, Pacheco-Barcia V, Dotor García-Soto J, et al. 2018. Predictors of unknown cancer in patients with ischemic stroke. Journal of Neuro-oncology 137:551−557

doi: 10.1007/s11060-017-2741-0
[13]

Lee MJ, Chung JW, Ahn MJ, Kim S, Seok JM, et al. 2017. Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-CANCER study. Journal of stroke 19:77−87

doi: 10.5853/jos.2016.00570
[14]

Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, et al. 2012. Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke 43:3029−3034

doi: 10.1161/STROKEAHA.112.658625
[15]

Navi BB, Iadecola C. 2018. Ischemic stroke in cancer patients: a review of an underappreciated pathology. Annals of Neurology 83:873−883

doi: 10.1002/ana.25227
[16]

Uaprasert N, Voorhees PM, Mackman N, Key NS. 2010. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. European Journal of Cancer 46:1790−1799

doi: 10.1016/j.ejca.2010.03.007
[17]

Coppola A, Tufano A, Di Capua M, Franchini M. 2011. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Seminars in Thrombosis and Hemostasis 37:929−945

doi: 10.1055/s-0031-1297372
[18]

Varki A. 2007. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110:1723−1729

doi: 10.1182/blood-2006-10-053736
[19]

Kim SJ, Park JH, Lee MJ, Park YG, Ahn MJ, et al. 2012. Clues to occult cancer in patients with ischemic stroke. PLoS One 7:e44959

doi: 10.1371/journal.pone.0044959
[20]

Nouh AM, Staff I, Finelli PF. 2019. Three Territory Sign: An MRI marker of malignancy-related ischemic stroke (Trousseau syndrome). Neurology. Clinical Practice 9:124−128

doi: 10.1212/CPJ.0000000000000603
[21]

Kim SG, Hong JM, Kim HY, Lee J, Chung PW, et al. 2010. Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke 41:798−801

doi: 10.1161/STROKEAHA.109.571356
[22]

Tsushima M, Metoki N, Hagii J, Saito S, Shiroto H, et al. 2020. D-dimer and C-reactive Protein as Potential Biomarkers for Diagnosis of Trousseau's Syndrome in Patients with Cerebral Embolism. Journal of Stroke and Cerebrovascular Diseases 29:104534

doi: 10.1016/j.jstrokecerebrovasdis.2019.104534
[23]

Ito S, Ueda A, Murate K, Hirota S, Fukui T, et al. 2016. Differentiation of cancer from atrial fibrillation in patients with acute multifocal stroke. Journal of the Neurological Sciences 368:344−348

doi: 10.1016/j.jns.2016.07.054
[24]

Nutting C, Camplejohn RS, Gilchrist R, Tait D, Blake P, et al. 2000. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clinical Oncology 12:300−304

doi: 10.1053/clon.2000.9179
[25]

Soerjomataram I, Coebergh JW. 2009. Epidemiology of multiple primary cancers. In Cancer Epidemiology. Methods in Molecular Biology, ed. Verma M. 471. Totowa, NJ: Humana Press. pp. 85−105 doi: 10.1007/978-1-59745-416-2_5
[26]

Lam AK, Chan SS, Leung M. 2014. Synchronous colorectal cancer: clinical, pathological and molecular implications. World Journal of Gastroenterology 20:6815−6820

doi: 10.3748/wjg.v20.i22.6815
[27]

Liu X, Goldblum JR, Zhao Z, Landau M, Heald B, et al. 2012. Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma. The American Journal of Surgical Pathology 36:1228−1233

doi: 10.1097/PAS.0b013e318253645a
[28]

Chen SC, Liu CJ, Hu YW, Yeh CM, Hu LY, et al. 2016. Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan. Gastric Cancer 19:490−497

doi: 10.1007/s10120-015-0482-3
[29]

Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, et al. 2017. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. British Journal of Haematology 178:72−80

doi: 10.1111/bjh.14638
[30]

Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan EL, et al. 2016. The breast-thyroid cancer link: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention 25:231−238

doi: 10.1158/1055-9965.epi-15-0833
[31]

Wu S, Powers S, Zhu W, Hannun YA. 2016. Substantial contribution of extrinsic risk factors to cancer development. Nature 529:43−47

doi: 10.1038/nature16166
[32]

Park SM, Lim MK, Jung KW, Shin SA, Yoo KY, et al. 2007. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. Journal of Clinical Oncology 25:4835−4843

doi: 10.1200/JCO.2006.10.3416
[33]

Li N. 2016. Platelets in cancer metastasis: to help the "villain" to do evil. International Journal of Cancer 138:2078−2087

doi: 10.1002/ijc.29847